Meichen Li (Likun Chen)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Metastatic Colorectal Cancer

Epidermal Growth Factor Receptor

Top Venues

Signal transduction and targeted therapy

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Meichen Li, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fang
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Meichen Li, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fang
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Meichen Li, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fang
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Meichen Li, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fang
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal transduction and targeted therapy 9 (1) (2024)
Meichen Li, Xue Hou, Jing Chen, Juan Yu, Meiting Chen, Na Wang, Baishen Zhang, Li-Kun Chen
Comparing organ-specific immune-related adverse events for immune checkpoint inhibitors: A Bayesian network meta-analysis. Clinical and translational medicine 11 (2) (2021)